OverviewSuggest Edit

Kodiak Sciences, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD.
TypePublic
Founded2009
HQZug, CH
Websitekodiak.com

Latest Updates

Employees (est.) (Mar 2020)39(+26%)
Job Openings7
Share Price (May 2021)$116.8(-3%)
Cybersecurity ratingAMore

Key People/Management at Kodiak Sciences

John Borgeson

John Borgeson

Senior Vice President and Chief Financial Officer
Victor Perlroth

Victor Perlroth

Chairman and Chief Executive Officer, Founder
Richard Levy

Richard Levy

Director
Charles Bancroft

Charles Bancroft

Director
Desiree Beutelspacher

Desiree Beutelspacher

Vice President of Clinical Operations
Jason Ehrlich

Jason Ehrlich

Chief Medical Officer and Chief Development Officer
Show more

Kodiak Sciences Office Locations

Kodiak Sciences has offices in Zug, Visp and Palo Alto
Zug, CH (HQ)
Dammstrasse 19
Visp, CH
Rottenstrasse 5
Palo Alto, CA, US
1200 Page Mill Rd
Palo Alto, CA, US
2631 Hanover St
Show all (4)

Kodiak Sciences Financials and Metrics

Kodiak Sciences Revenue

USD

Net income (FY, 2018)

(41.4m)

EBIT (FY, 2018)

(26.4m)

Market capitalization (3-May-2021)

6.0b

Closing stock price (3-May-2021)

116.8

Cash (31-Dec-2018)

88.3m
Kodiak Sciences's current market capitalization is $6 b.
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

3.1m3.5m7.6m

R&D expense

14.1m22.0m18.8m

Operating expense total

17.2m25.5m26.4m

EBIT

(17.2m)(25.5m)(26.4m)
USDFY, 2017FY, 2018

Cash

1.4m88.3m

Prepaid Expenses

200.0k2.2m

Current Assets

1.6m90.4m

PP&E

1.5m1.1m
USDFY, 2016FY, 2017FY, 2018

Net Income

(17.1m)(27.9m)(41.4m)

Depreciation and Amortization

257.0k549.0k490.0k

Accounts Payable

23.0k2.3m(2.3m)

Cash From Operating Activities

(16.0m)(17.7m)(29.0m)
Show all financial metrics

Kodiak Sciences Operating Metrics

Q2, 2018

Phase I Trials Products

1

Pre-Clinical Phase Products

3
Show all operating metrics

Kodiak Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Kodiak Sciences Financing Corporation
Kodiak Sciences GmbH

Kodiak Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Kodiak Sciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Kodiak Sciences Online and Social Media Presence

Embed Graph

Kodiak Sciences News and Updates

Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

PALO ALTO, Calif., March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial...

Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

PALO ALTO, Calif., Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced promising 1-year durability,...

Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock

PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an underwritten...

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that recruitment has concluded...

Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting

PALO ALTO, Calif., Nov. 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a pre-recorded presentation...

Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights

PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial...
Show more

Kodiak Sciences Blogs

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

PALO ALTO, Calif. , Feb. 2, 2021 /PRNewswire/ --  Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of clinical study

Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference

PALO ALTO, Calif. , Jan. 5, 2021 /PRNewswire/ --  Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the

Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PALO ALTO, Calif. , Nov. 20, 2020 /PRNewswire/ --  Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the closing of its previously announced

AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets

VANCOUVER, British Columbia & PALO ALTO, Calif.--( BUSINESS WIRE )-- AbCellera  and Kodiak Sciences Inc. (Nasdaq: KOD), today announced a new partnership to generate therapeutic antibody candidates in ophthalmology. Following a previously successful collaboration, AbCellera will use its full sta…

Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

- Concurrent development program compares Kodiak's long-acting anti-VEGF antibody biopolymer conjugate KSI-301 to standard of care in all major retinal disease indications: wet AMD, DME, and RVO.   - Kodiak also announces completion of U.S. patient enrollment in DAZZLE, its ongoing Phase 2b/3 study

Kodiak Sciences Appoints Charles Bancroft to Board of Directors

PALO ALTO, Calif. , April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of directors.
Show more

Kodiak Sciences Frequently Asked Questions

  • When was Kodiak Sciences founded?

    Kodiak Sciences was founded in 2009.

  • Who are Kodiak Sciences key executives?

    Kodiak Sciences's key executives are John Borgeson, Victor Perlroth and Richard Levy.

  • How many employees does Kodiak Sciences have?

    Kodiak Sciences has 39 employees.

  • Who are Kodiak Sciences competitors?

    Competitors of Kodiak Sciences include USV, Aurobindo Pharma and Patheon.

  • Where is Kodiak Sciences headquarters?

    Kodiak Sciences headquarters is located at Dammstrasse 19, Zug.

  • Where are Kodiak Sciences offices?

    Kodiak Sciences has offices in Zug, Visp and Palo Alto.

  • How many offices does Kodiak Sciences have?

    Kodiak Sciences has 4 offices.